Compare Gitlab Inc (GTLB) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Hims and Hers Health Inc — how do they compare? Gitlab Inc trades at $55.07 (market cap $8.92B), while Hims and Hers Health Inc trades at $30.92 (market cap $6.55B). The key difference: Gitlab Inc is the larger of the two by market cap, and Gitlab Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Hims and Hers Health Inc for 21 Days on average.
| GTLB | HIMS | |
|---|---|---|
Market Cap | $8.92B | $6.55B |
Volume | 4,716,893 | 14,842,814 |
Sector | Technology | Health |
52-Week High | $53.56 | $62.76 |
52-Week Low | $19.42 | $14.52 |
Typical Hold Time | 62 Days | 21 Days |
Enterprise Value | $7.66B | $7.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $55.09, up 5.96% today and near its 52-week high, with strong technical momentum. The company shows impressive revenue growth, reaching $759M in 2025, though it remains unprofitable with a net margin of -4.99%. Recent Q2 2026 earnings beat expectations with EPS of $0.24 versus $0.18 expected, driven by AI product traction and sales momentum. Analyst sentiment is mixed with a Hold consensus but positive news flow highlights AI-driven demand and raised guidance.
Outlook: GTLB benefits from AI integration in DevSecOps and strong execution, but high valuation (P/E 521) and persistent losses pose risks. Investment case hinges on sustained revenue growth and path to profitability. Key risks include competitive pressure and reliance on AI adoption trends.
Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.
The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
